The present disclosure relates to constructs useful in expressing biotinylated monomers and tetramers produced from these monomers. The present disclosure also relates to methods for production and use of these tetramers in identifying and isolating antigen specific B cells and cloning antibodies thereto.

The technology described herein is directed to polypeptide systems using drug-controlled peptide docking domains and cognate docking domain-binding peptides and their use to control cellular signaling, activity, and/or gene expression.

The present disclosure provides monoclonal antibodies that target intracytoplasmic inclusion bodies and/or hepacivirus C NS4A and methods for their use.

The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.

Disclosed herein is directed to a synthetic ribonucleic acid (RNA) fragment that includes an RNA template flanked by at least of 5′-end RNA-dependent RNA polymerase (RdRp) binding site and a 3′-end RdRp binding site, thus the synthetic RNA fragment can be amplified in vitro via an RNA-dependent RNA cycling reaction (RCR). Also disclosed herein is a method for producing an amplified RNA product by use of the present synthetic RNA fragment.

The application relates to an HCV recombinant antigen and a mutant thereof. The application provides an HCV recombinant antigen, the HCV recombinant antigen including at least 1 NS3 antigen, wherein at least one cysteine of the NS3 antigen in positions 1192-1517 of an HCV amino acid sequence is mutated into G and/or A, and preferably mutated into A. The application further provides a nucleic acid encoding the HCV recombinant antigen, an expression vector including the nucleic acid, a host cell including the expression vector, a conjugate including the HCV recombinant antigen, and a kit including the HCV recombinant antigen.

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.

The present disclosure relates to constructs useful in expressing biotinylated monomers and tetramers produced from these monomers. The present disclosure also relates to methods for production and use of these tetramers in identifying and isolating antigen specific B cells and cloning antibodies thereto.

Described herein are engineered fusion proteins comprising a variant protease (e.g., an HCV NS3 protease) fused to a polypeptide of interest and a cognate protease cleavage site. The cleavability of the cognate protease cleavage site enables the controllability of one or more functions of the polypeptide of interest. Additionally disclosed are methods for generating engineered fusion proteins as well as their therapeutic use.